Bristol-Myers Squibb $2PR (BMYMP) Net Income by Year
Bristol-Myers Squibb $2PR reported $7.1B in net income in fiscal year 2025. The change from the prior fiscal year is not meaningful, because that figure was zero or negative. Over the trailing 12 months, Q2 FY2025 through Q1 FY2026, the same line adds up to $7.3B in net income. The table below carries 15 fiscal years, from 2011 to 2025, and the quarters Bristol-Myers Squibb $2PR has filed alongside them.
Annual figures, oldest first. Point at a bar to read its period.
BMYMP Net Income by Fiscal Year
Figures are as reported in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.
TTM is the trailing twelve months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings.
BMYMP Net Income by Quarter
Figures are as reported in USD. Each change compares the quarter with the same quarter a year earlier.
What net income means
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line.
More Bristol-Myers Squibb $2PR financials
Frequently Asked Questions
Bristol-Myers Squibb $2PR reported $7.1B in net income in fiscal year 2025.
Bristol-Myers Squibb $2PR (BMYMP) reported a $8.9B net loss in fiscal year 2024 and $7.1B in net income in fiscal year 2025. A growth rate is not meaningful here, because the earlier figure was zero or negative.
Bristol-Myers Squibb $2PR (BMYMP) reported $7.3B in net income over the trailing 12 months, Q2 FY2025 through Q1 FY2026, summed from the four most recent quarterly filings.
Across the 15 fiscal years this page covers, Bristol-Myers Squibb $2PR (BMYMP) net income went from $3.7B in fiscal year 2011 to $7.1B in fiscal year 2025.
Bristol-Myers Squibb $2PR (BMYMP) reported $2.7B in net income in Q1 2026. This represents an increase of 9.0% from the same quarter a year earlier.
Net income is what is left of revenue once every cost is counted, interest and tax included, so a company can grow its sales and still report a loss on this line. This page lists what Bristol-Myers Squibb $2PR (BMYMP) reported on that line in every period on record.